Table 1.

Neutralization of HIV-1 JR-FL and YU2 by aplaviroc-conjugated BNmAbs and CD4-Ig

Antibodya	Avg no. of aplaviroc moieties per IgG molecule	IC50 (nM) for:
		JR-FL	YU2
b12-apl	0.5	0.1	0.1
b12	0	0.3	46.7
2G12-apl	2	0.3	25.5
2G12	0	0.8	>100
PG9-apl	1	11.6	1.2
PG9	0	>100	22.6
PG16-apl	2	5.9	0.4
PG16	0	>100	1.5
CD4-IgG–apl	1	0.6	0.6
CD4-IgG	0	0.6	0.7
Aplaviroc		0.95	0.86
2D7 (positive control)	0	0.2	0.1
DEN3 (negative control)	0	>1,000	>1,000

^aapl, aplaviroc.